GlassScriptPhysician profile
Mary K Cramer
NPI 1144670845
$4,875.34
in general payments reported to CMS, 2019-2025
34 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $245 · 2023: $1,145 · 2024: $1,610 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,208.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $817.93 | 2021-2025 | |
| Novo Nordisk INC | $637.67 | 2021-2025 | Wegovy, Ozempic, Saxenda |
| Abbvie INC. | $511.97 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $493.88 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $386.56 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $344.69 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $248.65 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $216.62 | 2024-2025 | Caplyta |
| Dexcom, INC. | $204.82 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $115.95 | 2022-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $86.57 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.11 | 2022-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| E.R. Squibb & Sons, L.L.C. | $71.66 | 2023-2025 | Eliquis, Camzyos |
| Idorsia Pharmaceuticals US INC | $68.12 | 2022-2024 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $54.73 | 2022-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $41.44 | 2024-2025 | Gemtesa |
| Lundbeck LLC | $41.00 | 2024-2025 | Rexulti |
| Boston Scientific Corporation | $39.91 | 2022-2024 | |
| Axsome Therapeutics, INC. | $39.61 | 2022-2025 | Auvelity |
| Philips North America LLC | $39.24 | 2024 | (Ck7) Extended Holter |
| Takeda Pharmaceuticals U.S.A., INC. | $39.17 | 2021-2023 | Trintellix |
| Esperion Therapeutics, INC. | $34.87 | 2021-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $30.82 | 2023 | |
| Astellas Pharma US INC | $29.78 | 2023 | Myrbetriq, Veozah |
| Silk Road Medical, INC. | $28.72 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Exact Sciences Corporation | $28.45 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $26.65 | 2024-2025 | Zoryve |
| Medtronic, INC. | $22.24 | 2025 | Minimed 780g |
| Otsuka America Pharmaceutical, INC. | $19.00 | 2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $18.46 | 2021 | |
| Dynavax Technologies Corporation | $16.80 | 2025 | Heplisav-B |
| Currax Pharmaceuticals LLC | $13.68 | 2023 | Contrave |
| Amarin Pharma, INC. | $12.60 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Cramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.